Joint committee of the DFG reprimands Professor Rolf-Hermann Ringert

July 11, 2005

At its meeting on 5 July 2005, the Joint Committee of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) issued a reprimand against the head of the Institute of Urology at the University Hospital of Göttingen, Professor Rolf-Hermann Ringert, after he was found to have violated the rules of good scientific practice. In addition to the reprimand, Professor Ringert will not be eligible to apply for DFG funding in the next eight years and will also not be able to serve as a peer reviewer during this time. Furthermore, he is denied the right to vote in DFG elections for the same period.

A study into the treatment of renal cell carcinoma was conducted at the Institute of Urology at Göttingen's University Hospital from 1996 onwards. Professor Ringert was - and still is - the head of the institute; he also served as an elected peer reviewer for the DFG between 1995 and 2003.

The treatment given to 17 cancer patients was based on the research findings published in the journal Nature Medicine 6, 332-336 (2000). The publication was subsequently found to contain a number of serious flaws, and was therefore withdrawn by the authors in September 2003.

The DFG's Committee of Inquiry on Allegations of Scientific Misconduct investigated the allegations of scientific misconduct made against Professor Ringert, building on the results of the inquiry conducted by Göttingen University. It came to the conclusion that the publication in Nature Medicine showed evidence of severe scientific misconduct. The committee was of the opinion that the flaws listed were to be regarded as false statements. Professor Ringert, as both the senior author of the paper and head of the clinical study as well as the head of the Institute of Urology where the study was conducted, is responsible for these flaws.

As an elected peer reviewer Professor Ringert played a key role in fulfilling the DFG's statutory goals - selecting the best projects through fair and transparent competition.

Deutsche Forschungsgemeinschaft

Related Urology Articles from Brightsurf:

European survey shows alarmingly low awareness of erectile dysfunction
Awareness of erectile dysfunction (ED) is alarmingly low in men and women aged 20 to 70, a new survey commissioned by the European Association of Urology (EAU) has revealed.

During the pandemic, online lecture series helps fill gaps in training for urology residents
The ongoing coronavirus pandemic has affected all aspects of healthcare - including sharp drops in educational opportunities for resident physicians in training.

Innovative, minimally invasive treatment can help maintain prostate cancer patients' quality of life
Focal HIFU ablation is an effective treatment for prostate cancer while maintaining continence and sexual function, as well as improving recovery time.

Antibiotic overuse is high for common urology procedures
A new study suggests that antibiotics are being overused in up to 60 percent of patients undergoing common urological procedures.

Alarmingly low awareness of urology across Europe
Results of a new international survey of more than 2,500 responders from five countries show that women know more about men's health issues than men do, men have poor knowledge of key urological symptoms and don't take early signs of potentially life-threatening urological conditions seriously.

Robert Flanigan, M.D., receives American Urological Association's highest honor
The American Urological Association has given Robert C. Flanigan, M.D., chair of Loyola Medicine's department of urology, the association's highest honor.

Pitt Urology Department opens cooperative research center
$7.7 million in funding from the NIH will help investigate important factors involved with BPH and lower urinary tract symptoms.

The gender divide in urology: Surgeon gender shapes the clinical landscape
Although female certified urologists are still a minority within the specialty, they perform many more procedures on women than their male colleagues, who perform more procedures on men than their female colleagues.

Radical treatment and examination combined can halve mortality from prostate cancer
Men with very high-risk prostate cancer, who are treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy), only have half of the mortality risk of men who are treated at hospitals with the lowest proportion.

No link found between erectile dysfunction drugs and risk of prostate cancer
While some previous studies have indicated that taking erectile dysfunction drugs may reduce the likelihood of developing prostate cancer, new research published in The Journal of Urology found that these drugs do not play a role in preventing prostate cancer.

Read More: Urology News and Urology Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to